Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-09-14
Schrödinger, Inc.
Schrödinger develops molecular design software and uses the same computational platform to support partnered and proprietary drug discovery.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Workflow Control Could Outgrow Model Access
The upside case is a shift from selling expert tools to owning governed discovery workflows. If agentic discovery lifts workflow embedment and program-level pricing, recurring software value can compound without needing a single jackpot drug outcome.

Analysis

Thesis
Over five years, the upside is a business-model upgrade more than a binary drug win: if hosted delivery, LiveDesign, and Bunsen let Schrödinger charge for governed discovery workflows and throughput, AI-driven discovery volume can expand revenue faster than seats while preserving selective milestone and royalty upside.
Last Economy Alignment
Cheaper cognition should increase discovery throughput, and Schrödinger has real workflow embedment plus validated simulation to capture some of that value. But it does not own compute or exclusive data rails, so open tools and in-house agents can still cap pricing power.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.6x (from 5 most recent analyses)
Reasoning
The rerating case is cleaner revenue quality, not a miracle drug outcome. If Schrödinger becomes the operating layer where teams plan, run, verify, and route discovery work, investors can pay a better multiple for more recurring and embedded software economics while still keeping some collaboration upside. If Bunsen only raises usage without raising paid workflow control, the multiple stays capped.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is economic capture, not scientific relevance. Schrödinger likely remains useful, but the equity case weakens if Bunsen increases activity without proving paid throughput, if large pharma keeps orchestration in-house, or if collaboration revenue stays too lumpy to offset software-transition noise. Customer concentration and short renewal cycles keep the proof burden high through 2027.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.40
They control a workflow that helps pharma teams plan, run, and track discovery work, so cheaper AI can send more activity through their system. The risk is that customers keep the data and decision layer in-house and use cheaper open tools underneath, which would limit how much value Schrödinger captures.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$21.43
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case